Innovestor Research
Investment Thesis
Innovestor is a Helsinki-based investment group founded in 2014, built around the idea of "Making Good Money" - backing businesses that create the greatest impact alongside strong financial returns. What began as an online co-investment platform has grown into one of the most active Nordic venture capital firms, now spanning six venture capital funds, a corporate venturing practice, a real estate business, and an energy storage business. Across all of these lines, Innovestor positions itself as a long-term partner to founders and asset owners rather than a single-round capital provider, emphasizing active ownership, deep sector networks, and hands-on operating support.
Stage Focus
Innovestor's venture capital arm targets early-stage companies and explicitly positions itself as the "first VC check" for entrepreneurs raising external capital. The Technology Fund invests from Seed through Series A. The Life Science Fund invests from Pre-Seed through Series A. The Angel CoFund complements both by co-investing alongside angel investor syndicates at the earliest stages, and the PALO Accelerator Program supports pre-seed sustainable technology startups.
Check Size
- Technology Fund: initial tickets of EUR 250K to EUR 1M
- Life Science Fund: initial tickets of EUR 250K to EUR 3M
- Angel CoFund: smaller co-investment checks alongside syndicates of angel investors, with active follow-on participation
Lead Tendency
Not explicitly disclosed on the website. Public deal coverage (e.g., the Actithera Series A) shows Innovestor participating alongside larger co-lead investors such as M Ventures, Sofinnova Partners, and Hadean Ventures rather than leading, though the firm's own "first VC check" positioning suggests it does lead at the earliest (Angel CoFund and pre-seed) stages. Treated as unknown pending more evidence.
Recent Activity
Innovestor has been actively deploying through 2025 and into 2026:
- January 2026: Reported 74 total investments across the group in 2025, alongside a real estate exit that included integrated battery systems.
- August 2025: The Life Science Fund made its 14th investment, co-investing in Actithera's USD 75.5M Series A alongside M Ventures, Hadean Ventures, Sofinnova Partners, 4BIO Capital, Bioqube Ventures, Investinor, Surveyor Capital, and Arkin Bio Ventures II.
- June 2025: Angel CoFund closed a busy first half with 9 new investments and 5 follow-on investments.
- November 2025: Innovestor completed the sale of four Finnish retail assets to Prisma Properties, an exit on the real estate side of the business.
- February 2026: Announced a partnership with Grid.vc to build a next-generation fund together.
- August 2026: Angel CoFund reported it had already exceeded the prior full year's investment pace within the first eight months of 2026, signaling continued acceleration.
Portfolio Highlights
Innovestor's venture portfolio spans well over 100 companies across technology and life science, including 73Health (remote medical examination SaaS), 7Signal Solutions (WiFi performance management), 9Solutions (digital health platform), Aatos (digital commerce), Abacus Diagnostica (diagnostics), Adeu AI (AI-powered legal time tracking), AegisNet (drone protection/defense tech), Aispeco (geospatial data collection), Alex Therapeutics (digital CBT therapeutics), Amertate (hybrid wind turbines), Amplifiles (AI property photo-to-video), Aplagon and Aurealis Pharma and Aranda Pharma (therapeutics), Arilyn (augmented reality as a service), and ArcDia International and BBS-Bioactive Bone Substitutes (medtech). The firm has also published research noting emerging trends across its growing AI portfolio, suggesting an increasing share of AI-native investments.
Team
- Wilhelm Lindholm - Group CEO
- Tommi Aijala - Group Chair
- Petri Laine - Venture Partner (spans Technology and Life Science funds)
- Piia Maaranen - Partner, Technology Fund
- Myron Seto - Partner, Technology Fund
- Mikko Rautiainen - Investment Manager, Technology Fund
- Lauri Karjalainen - Investment Manager, Technology Fund
- Marko Kuisma - Partner, Life Science Fund
- Milla Koistinaho - Partner, Life Science Fund
- Pekka Simula - Partner, Life Science Fund
- Sara Kangaspeska - Investment Director, Life Science Fund
- Emilia Carlqvist - Analyst, Life Science Fund
Decision Process
Both the Technology Fund and Life Science Fund are run by multi-partner teams (three partners plus investment managers/directors on each), consistent with a partnership-style decision process rather than a solo GP model.
Founder Preferences
Innovestor backs technical and scientific founders building breakthrough innovations aligned with global megatrends: enterprise/B2B and industrial technology on the Technology Fund side, and biotech/digital health addressing unmet medical needs on the Life Science Fund side. The firm emphasizes companies with international scaling potential rather than purely domestic Finnish plays.
Geographic Focus
Innovestor's venture funds are focused on the Nordics and Baltics region, headquartered in Helsinki, Finland, with a stated goal of giving Nordic and Baltic founders access to European growth capital and networks.
Assets Under Management
Approximately EUR 250M in assets under management across Innovestor's six venture capital funds, per the firm's own venture capital overview page.